Angiogenesis is the propelling force for @entity5 growth and @entity3 , and antiangiogenic therapy represents one of the most promising modalities for @entity5 treatment. @entity31973 (endoglin) is a proliferation-associated and @entity519 -inducible protein abundantly expressed in angiogenic endothelial cells (EC). It is a receptor for transforming growth factor (TGF) -beta1 and -beta3 and modulates TGF-beta signaling by interacting with TGF-beta receptors I and/or II. Immunohistochemistry studies have revealed that @entity31973 is strongly expressed in blood vessels of @entity5 tissues. Intratumoral microvessel density (MVD) determined using antibodies to @entity31973 has been found to be an independent prognostic indicator, wherein increased MVD correlates with shorter survival. @entity31973 is able to be shed into the circulation, with elevated levels detected in @entity1 with various types of @entity5 and positively correlated with @entity5 @entity3 . Tangible evidence of its proangiogenic role comes from knockout studies in which @entity31973 null @entity19 die in utero as a result of impaired angiogenesis in the yolk sac and @entity299 . The potential usefulness of @entity31973 for @entity5 imaging has been evaluated in @entity5 -bearing @entity19 and @entity235 that have shown the rapid accumulation of radiolabeled anti- @entity31973 monoclonal antibody in the @entity5 with a high @entity5 -to-background ratio. The anti- @entity31973 antibody conjugated with immunotoxins and immunoradioisotopes efficiently suppressed/abrogated @entity5 growth in @entity19 models bearing @entity0 without any significant systemic side effects. Immunoscintigraphy in @entity1 with @entity1358 has shown specific localization of 99Tcm-labeled @entity31973 mab in @entity5 endothelial cells. Thus, @entity31973 is a promising vascular target that can be used for @entity5 imaging, prognosis, and bears therapeutic potential in @entity1 with solid @entity5 and other @entity66 .

XXXX is important for angiogenesis: evidence and potential applications.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast and colon carcinoma'] @entity66 :: ('MESH:D004194', 'Disease') :: ['angiogenic diseases'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'tumors'] @entity31973 :: ('13805(Tax:10090)', 'Gene') :: ['CD105'] @entity19 :: ('10090', 'Species') :: ['mice', 'murine'] @entity235 :: ('9615', 'Species') :: ['dogs'] @entity519 :: ('MESH:D000860', 'Disease') :: ['hypoxia'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell carcinomas'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity299 :: ('MESH:D006331', 'Disease') :: ['heart defects']
@entity31973 :: (13805(Tax:10090),Gene) :: ['CD105']
